7 recruiting, 6 completed, 5 terminated, 4 active not recruiting. 26 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Recruiting 7, Completed 6, Terminated 5, Active not recruiting 4, Unknown 2, Withdrawn 2 |
| Phase 2 | 6 | Active not recruiting 2, Recruiting 2, Completed 1, Terminated 1 |
Follow Cutaneous Squamous Cell Carcinoma: new trials by email Literature Review of Cutaneous Squamous Cell Carcinoma trials Research Report on Cutaneous Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors tolododekin alfa, Cemiplimab - Advanced Solid Tumor, Cutaneous Tumor | Phase 1 | Recruiting | Ankyra Therapeutics, Inc | 97 | 2024-01-19 | 2026-03-06 |
| Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) Microneedle Array Doxorubicin (MNA-D) - Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Falo, Louis, MD | 48 | 2023-09-13 | 2026-04-09 |
| Cemiplimab/Peg-Interferon-α in Advanced CSCC Cemiplimab-Rwlc, PEG-IFN alfa-2a - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 | Withdrawn | Baptist Health South Florida | 2023-07-01 | 2023-08-09 | |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas IMT-009, Fruquintinib - Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Immunitas Therapeutics | 67 | 2022-11-28 | 2025-10-16 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors MEM-288 Intratumoral Injection, Nivolumab, Docetaxel - Solid Tumor, Advanced Cancer | Phase 1 | Recruiting | Memgen, Inc. | 40 | 2022-04-21 | 2026-06-11 |
| RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC RM-1995, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 1 | Withdrawn | Rakuten Medical, Inc. | 2022-03-24 | 2023-04-19 | |
| Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab-Rwlc - Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 36 | 2021-10-22 | 2026-06-25 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| IFx-Hu2.0 for the Treatment of Patients With Skin Cancer IFx-Hu2.0 - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Completed | TuHURA Biosciences, Inc. | 5 | 2021-06-10 | 2024-08-02 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors INCB099318 - Advanced Solid Tumors, MSI-H/dMMR Tumors | Phase 1 | Terminated | Incyte Corporation | 105 | 2021-03-26 | 2025-10-16 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy GEN-011, IL-2, Fludarabine - Melanoma, Non-small Cell Lung Cancer | Phase 1 | Terminated | Genocea Biosciences, Inc. | 49 | 2020-11-11 | 2022-07-15 |
| Cemiplimab in AlloSCT/SOT Recipients With CSCC Cemiplimab, Everolimus, Sirolimus - Cutaneous Squamous Cell Carcinoma, Advanced Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 12 | 2020-11-03 | 2025-04-23 |
| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Drug: SL-172154 - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Terminated | Shattuck Labs, Inc. | 5 | 2020-09-17 | 2025-02-24 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors INCB099280 - Advanced Solid Tumor, MSI-H/dMMR Tumors | Phase 1 | Completed | Incyte Corporation | 182 | 2020-09-04 | 2025-07-14 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors TBio-6517, Pembrolizumab - Solid Tumor, Microsatellite Stable Colorectal Cancer | Phase 1 | Terminated | Turnstone Biologics, Corp. | 27 | 2020-06-02 | 2025-04-23 |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors BCA101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal | Phase 1 | Recruiting | Bicara Therapeutics | 473 | 2020-06-01 | 2026-10-06 |
| Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers IFx-Hu2.0 - Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Phase 1 | Completed | TuHURA Biosciences, Inc. | 23 | 2020-03-03 | 2024-09-23 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Merkel Cell (11) · Squamous Cell Carcinoma of Head and Neck (10) · Carcinoma, Basal Cell (8) · Melanoma (8) · Skin Neoplasms (7) · Neoplasm Metastasis (6) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Renal Cell (5) · Carcinoma, Squamous Cell (5) · Head and Neck Neoplasms (5) · Neoplasms (5) · Carcinoma, Transitional Cell (4) · Uterine Cervical Neoplasms (4) · Anus Neoplasms (3) · Colorectal Neoplasms (3)
Neoplasms by Histologic Type (23) · Neoplasms, Glandular and Epithelial (23) · Carcinoma (22) · Neoplasms (19) · Neoplasms by Site (19) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Adenocarcinoma (12) · DNA Virus Infections (12) · Infections (12) · Neoplasms, Germ Cell and Embryonal (12) · Neoplasms, Nerve Tissue (12) · Neuroectodermal Tumors (12) · Neuroendocrine Tumors (12) · Tumor Virus Infections (12)
pembrolizumab (6) · cemiplimab (3) · Interleukin-2 (2) · Capecitabine (1) · Cetuximab (1) · Coat Protein Complex I (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Everolimus (1) · Glatiramer Acetate (1) · HMPL-013 (1) · Nivolumab (1) · Prednisone (1) · Radiation (1)
Incyte Corporation (2) · Memorial Sloan Kettering Cancer Center (2) · TuHURA Biosciences, Inc. (2) · Ankyra Therapeutics, Inc (1) · Baptist Health South Florida (1) · Bicara Therapeutics (1) · Checkpoint Therapeutics, Inc. (1) · Dana-Farber Cancer Institute (1) · Falo, Louis, MD (1) · Genocea Biosciences, Inc. (1) · Genzada Pharmaceuticals USA, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Immunitas Therapeutics (1) · InduPro, Inc. (1) · Medicenna Therapeutics, Inc. (1)
United States (24) · Australia (5) · Canada (4) · Belgium (2) · France (2) · South Korea (2) · Spain (2) · Denmark (1) · Finland (1) · Ireland (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Norway (1) · Poland (1)
Lara Dunn, MD (2) · Ahmad Tarhini, MD, PhD (1) · Andreas Saltos, MD (1) · Andrew S Brohl, MD (1) · Arash Yavari, MBBS (1) · Brian Gastman, MD (1) · Fumito Ito, MD (1) · Glenn J Hanna, MD (1) · Guilherme Rabinowits, M.D. (1) · Ines Verdon, MD (1) · Joaquina Baranda, MD (1) · Joseph Elassal, MD, MBA (1) · Kathryn Gazarik (1)
PMID 42580817, PMID 33477979, PMID 35276694, PMID 36821617, PMID 37848259, PMID 38252908, PMID 38758815, PMID 40230575, PMID 41022754, PMID 42102329
2019 (2), 2023 (1), P50CA254865 (1)